Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
My American Story
Roads, Travel and Traffic
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Jobs
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
My American Story
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Jobs
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Orbis Medicines
Orbis Medicines Enters Multi-Target Drug Discovery Partnership with Novo Nordisk Worth up to USD 1.4 Billion
September 17, 2026
From
Orbis Medicines
Via
Business Wire
Orbis Medicines Accelerates Next-Generation Oral Macrocycle Platform with Enhanced Artificial Intelligence Capabilities of Gefion Supercomputer
June 03, 2025
From
Orbis Medicines
Via
Business Wire
Orbis Medicines Names Veteran R&D Leader Mikael Dolsten Board Chair
March 05, 2025
From
Orbis Medicines
Via
Business Wire
Orbis Medicines Raises EUR 90 Million Series A Funding Round to Develop Pipeline of Oral Macrocycles
January 06, 2025
From
Orbis Medicines
Via
Business Wire
Orbis Medicines and Vivtex Form Research & Exclusive Licensing Collaboration to Support Orbis Development of Next-Generation Orally Dosable ‘nCycles’
September 17, 2024
From
Orbis Medicines
Via
Business Wire
Orbis Medicines Launches with €26 Million Seed Financing to Transform Macrocycle Drug Development through Next-Generation Orally Dosable ‘nCycles’
February 29, 2024
From
Orbis Medicines
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at
/week.
Subscribe Today